Author | Danielle Ternyila


Crizotinib Activity in MET-Altered Non-Small Cell Lung Cancer Undetermined

October 29, 2020

While the remarkable activity of crizotinib as treatment of patients with ROS1 fusion-positive advanced non–small cell lung cancer was confirmed in a recent systemic review and meta-analysis, the efficacy of this small molecular inhibitor remains unknown in patients with MET-altered disease.

High-Risk MCL Population Represents Unmet Need in Treatment Landscape

October 28, 2020

The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.